Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931 | 0.87 | ALDH1A1 (0.57) | ALDH1A1HPGDLMNAGRM5ALOX15 | |
| SCHEMBL10708175 | 0.80 | ALDH1A1 (0.66) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL14371962 | 0.79 | ALDH1A1 (0.65) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL3024050 | 0.77 | HPGD (0.62) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL3505447 | 0.77 | ALDH1A1 (0.61) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL1037003 | 0.76 | ALDH1A1 (0.65) | ALDH1A1HPGDLMNAGRM5OPRK1 | |
| SCHEMBL12247948 | 0.76 | LMNA (0.57) | ALDH1A1LMNAALOX15KDM4E | |
| SCHEMBL31055457 | 0.76 | HPGD (0.57) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL24150763 | 0.76 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAGRM5CTSA | |
| Hydrochloric Acid SCHEMBL10707808 | 0.76 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAGRM5CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 948/4885HPGD 1183/4885LMNA 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.